The Food and Drug Administration has quietly released a new report about the deaths of and injuries to women from the dangerous RU 486 abortion drug and the Obama administration has done nothing to make the information available to women.
Following its approval during the Clinton administration, the FDA released a report in 2006 that received widespread attention for showing more than 1,100 women had been subjected to “adverse effects” resulting from their taking the abortion drug mifepristone, commonly known a RU 486. Pro-life advocates have waited five years for the FDA to come out with a new report of problems associated with the drug — despite mounting evidence that the abortion drug continues to kill and injure women across the globe.
The FDA, with no fanfare, has released a new report, dated April 30, 2011. The report indicates 14 women in the United States alone have died from using the mifepristone abortion drug and 2,207 women have been injured by it.
Of the women experiencing medical and physical problems resulting from the abortion drug, 612 women required hospitalizations, 339 experienced blood loss significant enough to require a transfusion, 256 experienced infections and 48 women experienced what the FDA labeled as “severe infections.” Given that the RU 486 abortion drug caused sepsis, a potentially lethal infection that resulted in the deaths of women from around the world, the “serious infections” were very likely life-threatening situations.
“Severe infections generally involve death or hospitalization for at least 2-3 days, intravenous antibiotics for at least 24 hours, total antibiotic usage for at least 3 days, and any other physical or clinical findings, laboratory data or surgery that suggest a severe infection,” the FDA report states.
Women developing infections from usage of the RU 486 abortion drug experienced endometritis (involving the lining of the womb), pelvic inflammatory disease (involving the nearby reproductive organs such as the fallopian tubes or ovaries), and pelvic infections with sepsis (a serious systemic infection that has spread beyond the reproductive organs).
The FDA figures also reveal that abortion businesses like Planned Parenthood are still misusing the abortion drug.
Despite the FDA indicating, “Administration of mifepristone and misoprostol is contraindicated in patients with confirmed or suspected ectopic pregnancy (a pregnancy outside the uterus,” the abortion drug was given to women in 58 cases where they had an ectopic pregnancy.
Jeanne Monahan of the Family Research Council commented on the new report.
“The dangerous complications associated with this drug continue include hemorrhaging and infection. In the U.S., at least 612 women have been hospitalized after taking RU-486; and at least 339 women required blood transfusions as a result of serious blood loss after taking the abortion drug,” she said.
“Marketing the abortion drug as simple and painless, such as taking an aspirin, is dangerously misleading to women. RU-486 is in a class of drugs categorized as selective progesterone receptor modulators, which, in addition to blocking progesterone necessary for the developing baby, also suppresses a woman’s immune system. Additionally, it is sometimes the case that the remains of the pregnancy are not entirely expelled from a woman’s uterus, causing infection and other problems,” she said.
Monahan also complained about the usage of the mifepristone abortion drug in cases where an ectopic pregnancy was present.
“Clearly highlighting the need for more stringent medical oversight, the report also indicates that 58 women were prescribed RU-486 despite having ectopic pregnancies,” she said. “To state it more clearly, a woman who has an ectopic pregnancy and takes the RU 486 regimen places her life in danger.”
Monahan says the dangerous status of the abortion drug is not limited to the United States.
“It is not only women in the U.S. who are suffering as a result of chemical abortion, it is a worldwide trend. A recent Australian health department audit of nearly 10,000 abortions performed in 2009 and 2010 compared the safety of RU-486 with surgical abortion, with the outcome being in the words of one major media outlet “The Abortion Pill ‘Less Safe than Surgery,'” Monahan explained. “The Australian report showed that 1 in 18 patients who used RU-486 had to be re-admitted to hospitals (a total of 5.7% of women vs. only .4% of surgical abortions.) The same study revealed that as many as 33% of women who had second trimester RU-486 abortions required some form of surgical intervention.”
The report also indicated approximately 1.52 million women have used the dangerous abortion drug through the end of April 2001.
“Despite the seriousness and intensity of adverse effects related to RU-486, use of this form of abortion is on the rise, and frequently the regimen is dispensed with less medical oversight than surgical abortion,” Monahan said. “Even more troubling, nationally and internationally, “telemed” dissemination of RU-486 is increasing. Telemed abortions involved doctors proscribing RU-486 through Skype or over the Internet rather than during a patient visit.”
“The bottom line is that abortion drugs are not about improving women’s health but are more accurately about advancing a radical pro-abortion agenda regardless of the impact on women’s health, even when it proves deadly,” she concluded.